Floxuridine (FUDR)

From HemOnc.org - A Hematology Oncology Wiki
Jump to: navigation, search

General information

Class/mechanism: Pyrimidine analog, antimetabolite, inhibitor of thymidylate synthase. When given by rapid intraarterial injection, it is rapidly catabolized in vivo to fluorouracil (5-FU), which is metabolized to 5-fluoro-2'-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP). FdUMP inhibits DNA synthesis by binding to thymidylate synthase and inhibiting production of thymidylate; FUTP interferes with RNA processing when it is mistakenly incorporated in place of uridine triphosphate (UTP). When FUDR is given by continuous intraarterial infusion, direct anabolism to FUDR-monophosphate is enhanced, which increases the inhibition of DNA.[1][2]
Route: IA (intraarterial)
Extravasation: irritant

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Patient drug information

History of changes in FDA indication

  • 12/18/1970: Initial FDA approval


  1. 1.0 1.1 Floxuridine (FUDR) package insert
  2. Floxuridine (FUDR) package insert (locally hosted backup)
  3. Floxuridine (FUDR) patient drug information (Chemocare)
  4. Floxuridine (FUDR) patient drug information (UpToDate)